105
Participants
Start Date
October 16, 2015
Primary Completion Date
January 3, 2017
Study Completion Date
January 31, 2017
Nintedanib
Nintedanib 150mg bid
Pirfenidone
Osp. S. Giuseppe Fatebenefratelli, Milan
Lowcountry Lung and Crit Care, Charleston
HOP de la Cavale Blanche, Brest
HOP Pontchaillou, Rennes
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen
A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena
Minnesota Lung Center, Minneapolis
HOP Calmette, Lille
The Lung Research Center, LLC, Chesterfield
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg
HOP Louis Pradel, Bron
Tulane University Hospital and Clinic, New Orleans
HOP Bichat, Paris
HOP Avicenne, Bobigny
Klinik Donaustauf, Donaustauf
A.O.U. Policlinico Vittorio Emanuele, Catania
Western CT Medical Group, P.C., Danbury
Vanderbilt University Medical Center, Nashville
St. Paul's Hospital, Vancouver
Concordia Hospital, Winnipeg
HOP Pasteur, Nice
Sint Antonius Ziekenhuis, Nieuwegein
Erasmus Medisch Centrum, Rotterdam
Lead Sponsor
Boehringer Ingelheim
INDUSTRY